Add-on Sacubitril/Valsartan Therapy Induces Left Ventricular Remodeling in Non-responders to Cardiac Resynchronization Therapy to a Similar Extent as in Heart Failure Patients Without Resynchronization
ConclusionSV therapy induced similar improvements in echocardiographic parameters and in NT-proBNP levels in CRT-NR patients and in patients with HFrEF without resynchronization. (Source: Cardiology and Therapy)
Source: Cardiology and Therapy - January 12, 2024 Category: Cardiology Source Type: research
Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF
PIONEER-HF and the recently completed PARAGLIDE-HF both evaluated the efficacy and safety of sacubitril/valsartan in patients hospitalized with heart failure (HF). This prespecified pooled analysis of PIONEER-HF (Ejection fraction [EF] ≤40%) and PARAGLIDE-HF (EF>40%) examines outcomes with sacubitril/valsartan in patients stabilized after a worsening HF event across the spectrum of EF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: David A. Morrow, Eric Velazquez, Akshay Desai, Adam DeVore, Serge Lepage, Jeon-Gun Park, Kavita Sharma, Scott Solomon, Randall Starling, Jonathan Ward, Kristin Williamson, Shelley Zieroth, Adrian Hernandez, Robert Mentz, Eugene Braunwald Source Type: research
The Long-term Effect Of Sacubitril-Valsartan On Ventricular Arrhythmia Burden Detected By Implantable Cardioverter Defibrillator Among Ischemic Cardiomyopathy Patients With Reduced Ejection Fraction
Sacubitril-Valsartan (SV) reduced the risk of sudden cardiac death (SCD) among patients with heart failure and reduced ejection fraction (HFrEF), according to recent data. However, there are few and conflicting long-term data about the impact of SV on ventricular arrhythmias on the clinical context of ischemic cardiomyopathy (ICM) and implantable cardioverter defibrillator (ICD). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Konstantinos Polymeropoulos, Alexia Stavrati, Stellina Al-Kajed, George Tsinopoulos, Polydoros Lazaridis, Vassilios Tzalamouras, Stylianos Paraskevaidis Tags: 354 Source Type: research
Evidence-based Consensus On The Use Of Sacubitril Valsartan For Heart Failure Management In India
The PARADIGM-HF trial in 2014 established sacubitril/valsartan (SV) as an effective treatment for heart failure (HF). Recent trials support expanding its use and guidelines recommend its use. A consensus statement is being formulated to validate the contemporary evidence-based datasets for SV in managing HF and exploring its pleiotropic effects (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Jitendra Sawhney, Karthik Vasudevan, T. Shashikanth, Vashisth Das, K. Raghu, Naresh Goyal, Vishal Rastogi, Sameer Shrivastava, Balbir Singh, Ashwani Mehta, PV Suresh, G. Ranjit, Manoj Kumar, Priyank Jain, Anand Pandey Tags: 284 Source Type: research
Cardiac Remodeling Pattern In Patients With Heart Failure With Reduced Ejection Fraction Underwent Arni Treatment
Angiotension receptor -Neprilisyn inhibitiors; sacubitril-valsartan (ARNI) treatment is important in patients with heart failure with reduced ejection fraction. However, studies on the effects of ARNI and cardiac remodeling patterns are lacking. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Soo-Jin Kim Tags: 158 Source Type: research
Sacubitril/valsartan Vs Ace Inhibitor Use In Patients With Heart Failure With Reduced Ejection Fraction And New York Heart Association - 4 Symptoms; A Propensity Score Matched Analysis
Sacubitril/Valsartan is the first-line medication for patients with heart failure with reduced ejection fraction (HFrEF), evidence for which has come largely from the Paradigm-HF trial. Patients with New York Heart Association - 4 symptoms (NYHA-4) were underrepresented in this landmark trial with them being (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Bharat Rawlley, Andres Cordova Sanchez, Debanik Chaudhuri Tags: 081 Source Type: research
How Robust Is Paragon-HF? A Fragility Index Analysis
PARAGON-HF is a landmark randomized controlled trial comparing sacubitril-valsartan and valsartan alone in heart failure with preserved ejection fraction. Randomized controlled trials are the gold standard of evidence-based medicine, however frequently rely on using the p-value to determine statistical significance. This has led to the American Statistical Association publishing their first ever guidance statement on a specific statistical analysis in 2016, cautioning against over-reliance on the p-value. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Adam Pampori, Chonyang Albert Tags: 054 Source Type: research
Isovolumic Contraction Velocity In Heart Failure With Reduced Ejection Fraction And Effect Of Sacubitril/valsartan: The PROVE-HF Study
The load dependent left ventricular ejection fraction (LVEF) has been the cornerstone of systolic function assessment, yet its inherent limitations highlight the need for alternative prognostic measures of myocardial remodeling. We assessed the value of tissue-Doppler derived mitral annular isovolumic contraction velocity (ICV), a load independent measure of systolic function, in prediction of structural and functional cardiac changes after starting sacubitril/valsartan (sac/val) therapy in patients with heart failure with reduced ejection fraction (HFrEF). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Alaa M. Omar, Sean Murphy, Michael Felker, Ileana Pi ña, Javed Butler, Yuxi Liu, Reza Mohebi, Jonathan Ward, Kristin Williamson, Scott D. Solomon, James Januzzi, Johannita Contreras Tags: JNC-002 Source Type: research
Safety of sacubitril/valsartan among older adults. Where real world data meet clinical trials results
Heart failure is a condition that is increasing its prevalence around the world due to an increase in survival in conditions such as ischemic heart disease, and because of the increase of the prevalence of elderly individuals in our societies, as heart failure prevalence increases with age. [1,2] In spite of this demographical change most of the pivotal randomised clinical trials (RCT) on drugs for heart failure include a little proportion of patients with ages above 75 years old. Older patients are often underrepresented in RCT due to the high incidence of comorbidities that cause them to fail to meet the inclusion/exc...
Source: International Journal of Cardiology - December 31, 2023 Category: Cardiology Authors: Xavier Garcia-Moll, Laura Lopez Tags: Editorial Source Type: research
Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode
AbstractWorsening heart failure (HF) is a vulnerable period in which the patient has a markedly high risk of death or HF hospitalization (up to 10% and 30%, respectively, within the first weeks after episode). The prognosis of HF patients can be improved through a comprehensive approach that considers the different neurohormonal systems, with the early introduction and optimization of the quadruple therapy with sacubitril –valsartan, beta-blockers, mineralocorticoid receptor antagonists, and inhibitors. Despite that, there is a residual risk that is not targeted with these therapies. Currently, it is recognized that the ...
Source: ESC Heart Failure - December 30, 2023 Category: Cardiology Authors: Aleix Olivella,
Luis Almenar ‐Bonet,
Pedro Moliner,
Emmanuel Coloma,
Antoni Martínez‐Rubio,
Marco Paz Bermejo,
Ramon Boixeda,
German Cediel,
Ana Belén Méndez Fernández,
Lorenzo Facila Rubio Tags: Review Source Type: research
Finding new echocardiographic parameters for reverse cardiac remodeling
In a post hoc analysis of the PROVE HF study (Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure)[1], Omar et al[2] examined a load independent measure of systolic function, isovolumic contraction velocity (ICV), and assessed whether it represented an independent predictor of reverse cardiac modeling (i.e index left ventricular (LV) volume, left atrial volume index, left ventricular mass index, E/e ’, and ejection fraction recovery), health status using the Kansas City Cardiomyopathy Questionnaire, and changes in biomarkers (NT-proBNP, hs...
Source: Journal of Cardiac Failure - December 29, 2023 Category: Cardiology Authors: Estefania Oliveros, Julia Grapsa Tags: Editorial Comment Source Type: research
Correction to: Functional changes in the heart after sacubitril/valsartan use in 5 hemodialysis patients with hypertension. Case report
(Source: CEN Case Reports)
Source: CEN Case Reports - December 28, 2023 Category: Urology & Nephrology Source Type: research
ΔRDW Could Predict Major Adverse Cardiovascular Events in Patients with Heart Failure with Reduced Ejection Fraction After Sacubitril/Valsartan Treatment
(Source: International Journal of General Medicine)
Source: International Journal of General Medicine - December 19, 2023 Category: General Medicine Tags: International Journal of General Medicine Source Type: research
Impact of Treatment With Sacubitril/Valsartan on Erectile Dysfunction in Patients With Heart Failure With Reduced Ejection Fraction
The objective of this study was to assess the effects of S/V on erectile dysfunction in patients with heart failure with reduced ejection fraction (HFrEF). A prospective, open-label study was conducted with 59 male patients diagnosed with HFrEF and concomitant erectile dysfunction. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - December 13, 2023 Category: Cardiology Authors: Hasan Ali Barman, Omer Dogan, Selim Tanyola ç, Adem Atıcı, Hidayet Ozan Arabaci, Abdullah Omer Ebeoglu, Serhan Özyıldırım, Zerrin Yiğit Source Type: research
Sacubitril/valsartan: Where mechanism meets evidence ‐based medicine
(Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - December 12, 2023 Category: Cardiology Authors: Sonia Rivas Garc ía,
Jesús Álvarez‐García Tags: Invited Editorial Source Type: research
